MedReleaf to Sponsor Cancer Trial in Collaboration with the Ontario Clinical Oncology Group
In affiliation with Hamilton Health Sciences and the Department of Oncology at McMaster University
MARKHAM, ON, July 12, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), in collaboration with the Ontario Clinical Oncology Group ("OCOG") today announced it will sponsor a cancer trial to improve the management of cancer pain using medical grade cannabis oil.
The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management and palliative care is the Principal Investigator. The study will be conducted at the HHS Juravinski Cancer Centre in Hamilton over a one-two year period. Patients with cancer related pain will be administered MedReleaf's uniquely formatted cannabis oil capsules with the objective of improving pain management.
Cancer patients experiencing pain despite other pain medications may be eligible to participate. The aim of the trial is to assess the effect of cannabis oil in relieving their symptoms and to gain information on the best oral dosing regimen. Patients will receive an oil combining THC and CBD.
"Patients with cancer often suffer from significant pain and we know that while managing the pain with narcotics is often necessary, it is also fraught with issues," said Dr. Marissa Slaven. "Anecdotally, cancer patients have been telling us that cannabis products help their pain. Thanks to MedReleaf's commitment to advancing medical science we will now be able to start gathering the data needed to help our patients live better."
"Collaborating with the Ontario Oncology Group under the direction of Dr. Levine and its affiliates speaks to MedReleaf's foundation as an R&D driven company," said Neil Closner, CEO MedReleaf. "We are thrilled to have the opportunity to be involved in this important cancer trial which has the potential to positively impact the lives of cancer patients while advancing our understanding of the therapeutic benefits of medical cannabis and validating new treatment options for patients."
About OCOG
OCOG is an academic trials group based in the Escarpment Cancer Research Institute, a joint research institute of Hamilton Health Sciences and McMaster University. OCOG works with networks of investigators to design and conduct cancer clinical trials provincially, nationally, and beyond. OCOG was established in 1982 and since then over 12,000 patients have been entered in OCOG studies. The results of which have impacted on clinical care.
For more information on this and other cancer clinical trials, please visit www.ocog.ca
About MedReleaf Corp.
Canada's most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of industry leading, top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market. We serve the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit www.medreleaf.com or follow @medreleaf
SOURCE MedReleaf Corp.
Denise Riposati, Corporate Communications, [email protected], 289.317.1000 ext. 1118
Share this article